Please assess the completion status of the following clinical trial:

Trial Title: Study of Aripiprazole (Abilify) in Children With Symptoms of Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients ages 4-9 years (inclusive)~* Patients who are anticipated to have a Young Mania Rating Scale (Young et al. 1978) of 15 or higher at baseline~* Meet DSM-IV criteria for bipolar disorder type 1 or 2, cyclothymia, or bipolar disorder not otherwise specified (BP NOS) based on the results of both a semi-structured diagnostic research assessment (K-SADS-PL supplemented with mood disorder sections from the WASH-U K-SADS) (Geller et al., 2001; Kaufman et al., 1997) and a clinical interview with a child and adolescent psychiatrist.~Exclusion Criteria:~* Patients who have a history of intolerance to APZ at doses of 0.1mg/kg/day~* Patients who have experienced a manic episode with a documented APZ dose as monotherapy treatment of 0.2 mg/kg/day~* Patients with an active neurological/medical disorder for which treatment with APZ would be contraindicated~* Patients with clinical evidence of autistic disorder, Asperger's disorder, Rett's syndrome or other pervasive developmental disorders~* Patients with clinical evidence of mental retardation~* Patients who are known to be allergic or hypersensitive to aripiprazole~* Patients who are unable to swallow pills/capsules~* Patients for whom the need for hospitalization during the course of the study appears likely~* Patients who have a general medical or neurological condition (including clinically significant abnormalities on screening laboratories) that may be considered to be the etiology of the patient's mood disorder~* Patients who have a general medical or neurological condition for which treatment with an atypical antipsychotic would be contraindicated (e.g. tardive dyskinesia)~* Patients who have a general medical or neurological condition that could interfere with the interpretation of clinical response to APZ treatment~* Patients taking psychotropic agents (other than psychostimulants) within one week of baseline (2 weeks for fluoxetine; 3 days for psychostimulants)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 9 Years
- Healthy Volunteers: t

Study Arms:
- Aripiprazole (Type: ACTIVE_COMPARATOR): Phase I and Phase III are open label Abilify phases where all subjects receive active Abilify
- Placebo (Type: PLACEBO_COMPARATOR): in Phase 2 subjects are randomized to either placebo or abilify for up to 72 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).